Literature DB >> 14963406

Low dose fractionated radiation potentiates the effects of taxotere in nude mice xenografts of squamous cell carcinoma of head and neck.

Paul M Spring1, Susanne M Arnold, Shahin Shajahan, Brandee Brown, Swatee Dey, Subodh M Lele, Joseph Valentino, Raleigh Jones, Mohammed Mohiuddin, Mansoor M Ahmed.   

Abstract

This study evaluated the combined effect of Low Dose Fractionated Radiation (LDFRT) and Taxotere (TXT) therapy on the growth of SCCHN (squamous cell carcinoma of head and neck; SQ-20B, a p53 mutant SCCHN cell line) tumors in a nude mouse model to exploit the increased hyper radiation sensitivity (HRS) phenomenon present in G(2)/M cell cycle phase when induced by low doses of radiation that was demonstrated in in vitro settings. Seventy-eight animals were randomized into one control group and 5 treatment groups (treatments were administered weekly for six weeks). Tumor regression was observed in all the groups, however, tumor regression was not significant in 2 Gy or TXT or 2 Gy plus TXT treated groups when compared to control group. The tumor regression was significant in both the LDFRT group (p < 0.0043) and LDFRT + TXT group (p < 0.0006) when compared to other groups. A significantly prolonged tumor growth delay was observed in LDFRT group (p < 0.0081). Importantly, in combination of TXT and LDFRT, no tumor regrowth was observed in 12 out of 13 mice since LDFRT + TXT treatment caused a sustained regression of tumors for 9 weeks. Molecular analysis of resected tumor specimens demonstrated that Bax levels were elevated with concomitant increase in cytochrome c release to the cytosol of the treatment Group VI. These findings strongly suggest that LDFRT can be used in combination with TXT to potentiate the effects of drug on tumor regression through an apoptotic mode of death. Furthermore, the G(2)/M cell cycle arrest by TXT appears to be an important component of the enhanced apoptotic effect of TXT + LDFRT combined treatment.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14963406

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  14 in total

Review 1.  Exploiting sensitization windows of opportunity in hyper and hypo-fractionated radiation therapy.

Authors:  Anish Prasanna; Mansoor M Ahmed; Mohammed Mohiuddin; C Norman Coleman
Journal:  J Thorac Dis       Date:  2014-04       Impact factor: 2.895

2.  p16INK4a Status and Response to Induction Low-Dose Fractionated Radiation in Advanced Head and Neck Cancer.

Authors:  Natalie L Silver; Susanne M Arnold; John F Gleason; Mahesh Kudrimoti; Yolanda Brill; Emily V Dressler; Joseph Valentino
Journal:  Ann Otol Rhinol Laryngol       Date:  2015-03-25       Impact factor: 1.547

3.  Comparison of two radiation techniques for the breast boost in patients undergoing neoadjuvant treatment for breast cancer.

Authors:  Maria C De Santis; Luigia Nardone; Barbara Diletto; Roberta Canna; Michela Dispinzieri; Lorenza Marino; Laura Lozza; Vincenzo Valentini
Journal:  Br J Radiol       Date:  2016-07-25       Impact factor: 3.039

4.  Low-dose fractionated radiation with induction chemotherapy for locally advanced head and neck cancer: 5 year results of a prospective phase II trial.

Authors:  John F Gleason; Mahesh Kudrimoti; Emily M Van Meter; Mohammed Mohiuddin; William F Regine; Joseph Valentino; Daniel Kenady; Susanne M Arnold
Journal:  J Radiat Oncol       Date:  2013-03-01

5.  Low-dose fractionated radiotherapy and concomitant chemotherapy in glioblastoma multiforme with poor prognosis: a feasibility study.

Authors:  Mario Balducci; Silvia Chiesa; Barbara Diletto; Giuseppe Roberto D'Agostino; Annunziato Mangiola; Stefania Manfrida; Giovanna Mantini; Alessio Albanese; Alba Fiorentino; Vincenzo Frascino; Berardino De Bari; Francesco Micciche'; Fiorenza De Rose; Alessio Giuseppe Morganti; Carmelo Anile; Vincenzo Valentini
Journal:  Neuro Oncol       Date:  2011-10-12       Impact factor: 12.300

6.  The effects of G2-phase enrichment and checkpoint abrogation on low-dose hyper-radiosensitivity.

Authors:  Sarah A Krueger; George D Wilson; Evano Piasentin; Michael C Joiner; Brian Marples
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-08-01       Impact factor: 7.038

7.  Low-dose fractionated radiotherapy and concomitant chemotherapy for recurrent or progressive glioblastoma: final report of a pilot study.

Authors:  M Balducci; B Diletto; S Chiesa; G R D'Agostino; M A Gambacorta; M Ferro; C Colosimo; G Maira; C Anile; V Valentini
Journal:  Strahlenther Onkol       Date:  2014-01-17       Impact factor: 3.621

8.  Three-times daily ultrafractionated radiation therapy, a novel and promising regimen for glioblastoma patients.

Authors:  Patrick Beauchesne
Journal:  Cancers (Basel)       Date:  2013-09-25       Impact factor: 6.639

9.  Impact of time interval and dose rate on cell survival following low-dose fractionated exposures.

Authors:  Shingo Terashima; Yoichiro Hosokawa; Eichi Tsuruga; Yasushi Mariya; Toshiya Nakamura
Journal:  J Radiat Res       Date:  2017-11-01       Impact factor: 2.724

10.  The role of nitric oxide radicals in removal of hyper-radiosensitivity by priming irradiation.

Authors:  Nina Jeppesen Edin; Joe Alexander Sandvik; Hilde Synnøve Vollan; Katharina Reger; Agnes Görlach; Erik Olai Pettersen
Journal:  J Radiat Res       Date:  2013-05-17       Impact factor: 2.724

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.